A detailed history of Israel Englander (Millennium Management LLC) transactions in Ultragenyx Pharmaceutical Inc. stock. As of the latest transaction made, Millennium Management LLC holds 710,689 shares of RARE stock, worth $32.7 Million. This represents 0.02% of its overall portfolio holdings.

Number of Shares
710,689
Previous 1,850,734 61.6%
Holding current value
$32.7 Million
Previous $76.1 Million 48.1%
% of portfolio
0.02%
Previous 0.04%

Shares

25 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

SELL
$40.21 - $59.36 $45.8 Million - $67.7 Million
-1,140,045 Reduced 61.6%
710,689 $39.5 Million
Q2 2024

Aug 14, 2024

BUY
$37.42 - $51.61 $42.8 Million - $59 Million
1,142,829 Added 161.44%
1,850,734 $76.1 Million
Q1 2024

May 15, 2024

BUY
$43.02 - $53.69 $29.2 Million - $36.5 Million
679,353 Added 2379.35%
707,905 $33.1 Million
Q4 2023

Feb 14, 2024

SELL
$31.73 - $49.19 $853,314 - $1.32 Million
-26,893 Reduced 48.5%
28,552 $1.37 Million
Q2 2023

Aug 14, 2023

SELL
$37.35 - $52.15 $26.4 Million - $36.8 Million
-706,402 Reduced 92.72%
55,445 $2.56 Million
Q1 2023

May 15, 2023

SELL
$36.99 - $48.71 $402,451 - $529,964
-10,880 Reduced 1.41%
761,847 $30.6 Million
Q4 2022

Feb 14, 2023

BUY
$33.72 - $46.33 $16.1 Million - $22.1 Million
477,325 Added 161.58%
772,727 $35.8 Million
Q3 2022

Nov 14, 2022

BUY
$39.96 - $66.14 $6.86 Million - $11.3 Million
171,571 Added 138.55%
295,402 $12.2 Million
Q2 2022

Aug 15, 2022

BUY
$45.8 - $85.4 $5.33 Million - $9.94 Million
116,413 Added 1569.33%
123,831 $7.39 Million
Q1 2022

May 16, 2022

SELL
$62.2 - $84.4 $3.47 Million - $4.71 Million
-55,822 Reduced 88.27%
7,418 $539,000
Q4 2021

Feb 14, 2022

SELL
$73.71 - $87.86 $3.28 Million - $3.91 Million
-44,524 Reduced 41.32%
63,240 $5.32 Million
Q3 2021

Nov 15, 2021

SELL
$77.92 - $102.4 $35.5 Million - $46.7 Million
-455,623 Reduced 80.87%
107,764 $9.72 Million
Q2 2021

Aug 16, 2021

BUY
$92.19 - $115.71 $51.7 Million - $64.9 Million
561,292 Added 26791.98%
563,387 $53.7 Million
Q4 2020

Feb 16, 2021

SELL
$84.4 - $177.39 $325,615 - $684,370
-3,858 Reduced 64.81%
2,095 $290,000
Q3 2020

Nov 16, 2020

SELL
$72.98 - $90.0 $3.62 Million - $4.46 Million
-49,570 Reduced 89.28%
5,953 $489,000
Q2 2020

Aug 14, 2020

BUY
$46.91 - $78.22 $1.98 Million - $3.3 Million
42,129 Added 314.54%
55,523 $4.34 Million
Q1 2020

May 14, 2020

BUY
$33.8 - $62.9 $452,717 - $842,482
13,394 New
13,394 $595,000
Q4 2019

Feb 14, 2020

SELL
$36.08 - $45.83 $209,733 - $266,409
-5,813 Closed
0 $0
Q3 2019

Nov 14, 2019

BUY
$42.5 - $63.11 $247,052 - $366,858
5,813 New
5,813 $248,000
Q4 2018

Feb 14, 2019

SELL
$38.89 - $77.3 $675,208 - $1.34 Million
-17,362 Closed
0 $0
Q3 2018

Nov 14, 2018

BUY
$71.81 - $90.15 $1.25 Million - $1.57 Million
17,362 New
17,362 $1.33 Million
Q2 2018

Aug 14, 2018

SELL
$48.54 - $85.31 $14.6 Million - $25.6 Million
-300,260 Closed
0 $0
Q1 2018

May 15, 2018

BUY
$44.33 - $58.52 $7.82 Million - $10.3 Million
176,425 Added 142.47%
300,260 $15.3 Million
Q4 2017

Feb 14, 2018

BUY
$43.54 - $57.32 $1.62 Million - $2.14 Million
37,315 Added 43.13%
123,835 $5.74 Million
Q3 2017

Nov 14, 2017

BUY
$49.79 - $66.32 $4.31 Million - $5.74 Million
86,520
86,520 $4.61 Million

Others Institutions Holding RARE

About Ultragenyx Pharmaceutical Inc.


  • Ticker RARE
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 70,036,896
  • Market Cap $3.22B
  • Description
  • Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast...
More about RARE
Track Israel Englander's Portfolio

Track Israel Englander Portfolio

Follow Israel Englander (Millennium Management LLC) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Millennium Management LLC, based on Form 13F filings with the SEC.

News

Stay updated on Millennium Management LLC and Israel Englander with notifications on news.